The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Open-label extension study of the RNAi therapeutic ALN-VSP02 in cancer patients responding to therapy.
Maria Alsina
No relevant relationships to disclose
Josep Tabernero
No relevant relationships to disclose
Geoffrey Shapiro
No relevant relationships to disclose
Howard Burris
No relevant relationships to disclose
Jeffrey R. Infante
No relevant relationships to disclose
Glen J. Weiss
No relevant relationships to disclose
Andres Cervantes-Ruiperez
No relevant relationships to disclose
Mrinal M. Gounder
No relevant relationships to disclose
Luis Paz-Ares
No relevant relationships to disclose
Rick Falzone
Employment or Leadership Position - Alnylam
Stock Ownership - Alnylam
Jamie Hill
Employment or Leadership Position - Alnylam
Stock Ownership - Alnylam
Jeffrey Cehelsky
Employment or Leadership Position - Alnylam
Stock Ownership - Alnylam
Akshay Vaishnaw
Employment or Leadership Position - Alnylam
Stock Ownership - Alnylam
Jared Gollob
Employment or Leadership Position - Alnylam
Stock Ownership - Alnylam
Patricia LoRusso
No relevant relationships to disclose